Glioblastoma Clinical Trials in Baltimore, Maryland
9 recruitingBaltimore, Maryland
Showing 1–9 of 9 trials
Recruiting
Phase 2
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled317 locationsNCT06325683
Recruiting
Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
NovoCure GmbH741 enrolled82 locationsNCT06556563
Recruiting
Phase 1
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Not Applicable
LITT Followed by Hypofractionated RT for Recurrent Gliomas
NeoplasmsBrain TumorGlioblastoma+1 more
University of Maryland, Baltimore32 enrolled4 locationsNCT04181684
Recruiting
Phase 1
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins50 enrolled1 locationNCT05083754
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Breast CancerOvarian CancerEndometrial Cancer+40 more
Massive Bio, Inc.50,000 enrolled68 locationsNCT03452774
Recruiting
Phase 1
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
GlioblastomaMalignant GliomaRecurrent Glioblastoma+3 more
Sabine Mueller, MD, PhD20 enrolled20 locationsNCT04323046
Recruiting
Not Applicable
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
Brain TumorGlioblastomaGlioma
University of Maryland, Baltimore32 enrolled5 locationsNCT04699773
Recruiting
Phase 1Phase 2
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Glioblastoma
SignPath Pharma, Inc.30 enrolled2 locationsNCT05768919